Newscast – Page 132 – media

Medical Devices Exploring the Impact of the New European Directive on the Pharmaceutical Industry

Pedro Pala, Clinical Trial Supply Manager, Bial, explores the implications of the new EU Clinical Trials Regulation
- Source: clinicaltrialsarena
- 960
- December 20, 2017
Directive EU polices
Surgery of the future

First of all, a 3D model of the patient was been created before surgery, combining images previously acquired via an MRI scanner, or radiography. On the day of the operation, a 3D image was (virtually) projected on the patient, and helped Dr Grégory in any of his movements and decision making.
- Source: leyton
- 705
- December 20, 2017
Researches Surgery of the future
Silencing ‘junk’ gene could halt tumor growth

The gene is in an area of the genome that does not contain instructions for making proteins. At one time, it was thought that this non-coding area was just irrelevant "junk."
- Source: Medicalnewstoday
- 534
- December 20, 2017
cancer Researches tumor
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy

Spark Therapeutics $ONCE has scored an historic FDA approval of Luxturna, the world’s first such AAV-delivered gene therapy designed to cure a rare eye disease triggered by a genetic mutation. The drug is OK’d for RPE65 mutation linked retinal dystrophy. The treatment uses a viral vector to insert the correct copy of a gene retinal cells need to create a protein that turns light into electric signals which can restore vision lost to the disease. As with the earlier pioneering approval of the world’s first CAR-T, FDA commissioner Scott Gottlieb did the honors in recognizing the importance of this approval. And he says the agency will make sure that the regulatory path is straight and clear for the rest of the field looking to following Spark’s footsteps. “We’re at a turning point when it comes to this novel form of therapy and at the FDA, we’re focused on establishing ...
- Source: drugdu
- 752
- December 20, 2017
FDA genetic mutation. Luxturna New Approvals rare eye disease
Ultragenyx Sells Priority Review Voucher for $130 million

“The sale of the PRV provides us with an important source of non-dilutive capital to help advance our pipeline of rare and ultra-rare therapies, and accelerates the availability of these potential therapies to patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
- Source: finance.yahoo
- 716
- December 20, 2017
FDA Market Views Novartis PRV
Are You Doing A Good Job In Bed?

A lack of sleep has been linked to high blood pressure and other cardiovascular ailments, mental health conditions like depression and weight-related issues such as obesity and diabetes.
- Source: msn
- 660
- December 20, 2017
diabetes high blood pressure obesity Researches sleep
Blockchain Health Tech Company Launches with $3.5 Million Seed

Curisium, a new healthcare technology that builds blockchain-based contracting technology for payers, providers, and life sciences companies, officially launche with the announcement that it has secured $3.5 million in seed funding.
- Source: hcanews
- 652
- December 19, 2017
Market Views Sanofi seed funding Series
Artificial Intelligence Could Help in Breast Cancer Diagnosis

Researchers say AI procedure was successful in detecting the spread of breast cancer. It’s the latest artificial intelligence innovation in the medical world.
- Source: healthline
- 650
- December 19, 2017
Artificial Intelligence breast cancer Researches
Electric eel-inspired devices could power artificial human organs

A flexible and transparent power source inspired by the electric eel could be used to power electrical devices in the body, such as cardiac pacemakers, implantable sensors or even prosthetic organs. The prototype, described in Nature1 on 13 December, runs on a solution of salt and water, but researchers hope that future versions might get their energy from bodily fluids.
- Source: nature
- 450
- December 19, 2017
electrical devices Researches
US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO® (osimertinib), a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with clinical activity against central nervous system (CNS) metastases, in the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 (L858R) substitution mutations). The FDA has granted TAGRISSO Priority Review status, and previously granted Breakthrough Therapy Designation for TAGRISSO in the 1st-line treatment of patients with metastatic EGFR mutation-positive (EGFRm) NSCLC.
- Source: finance.yahoo
- 613
- December 19, 2017
AstraZeneca CNS FDA New Approvals NSCLC TAGRISSO®

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.